Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

What's the purpose of this trial?

Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.

ARM 1 is a, non-randomized, open label, multi-site Phase 1 study. CART-ddBCMA is a BCMA directed CAR with a non-scFv binding domain that has been deimmunized.

This trial is currently open and accepting patients.

What will happen during the trial?

Additional Trial Information

Phase 1

Enrollment: 12 patients (estimated)

View More

Published Results

Arcellx Announces Presentation of Positive Clinical Results from Ongoing Phase 1 Study of CART-ddBCMA at the 2021 ASCO Annual Meeting

June 04, 2021

As previously announced, as of the April 14, 2021 data cutoff:

  • 12 of 12 patients achieved responses per IMWG criteria (median follow-up of 197 days; (Min – Max) 29-449 days)
    • 5 patients achieved stringent complete responses (sCR)
    • 1 patient achieved a complete response (CR)
    • 3 patients achieved very good partial responses (VGPR)
    • 3 patients achieved partial responses (PR)
  • One patient achieved VGPR despite prior progression on BCMA-targeted therapy
  • Responses in 11 patients are ongoing, with evidence that responses deepen over time

All patients enrolled in the study have poor prognostic factors with 10 of 12 patients penta-refractory and all 12 patients having had at least three prior treatments.

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


University of Chicago Medicine Comprehensive Cancer Center

Chicago, IL

Open and Accepting


Massachusetts General Hospital

Boston, MA

Open and Accepting

Beth Israel Deaconess Medical Center

Boston, MA

Open and Accepting


Medical College of Wisconsin Froedtert Hospital

Milwaukee, WI

Open and Accepting

Trial Links

Read the latest news and updates on this trial.

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Arcellx, Inc. to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors